Where does Tubulis's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Tubulis's 1 recorded funding rounds.

Premier Alternatives

Tubulis

Drug Discovery · Planegg-Martinsried, Germany · Founded 2012 · Privately Held (backing)

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. Tubulis is based in Planegg-Martinsried, Germany and was founded in 2012. It was valued at $5.8 billion at a merger or acquisition in Apr 2026, the last priced event on record. It has raised $618 million across 1 recorded round; the latest was a $361 million Series C in Oct 2025.

PMV mark · valuation

$5.8B

Oct 2026

Priced at

a merger or acquisition

Apr 2026

Total raised

$618.5M

Last round

Later Stage VC (Series C)

Oct 2025

Cap table — not yet on record

Tubulis's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of Tubulis with a free account

·The complete investor list: 26 names
·Everyone on the team, board and advisors included
·Watch Tubulis: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about Tubulis

Where does Tubulis's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Tubulis's 1 recorded funding rounds.